Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.

Increased predisposition of schizophrenia patients (SP) to development of obesity and insulin resistance suggested common signaling pathway between metabolic syndrome (MetS) and schizophrenia. Deficiency of kynurenine-3-monooxygenase (KMO), enzyme catalyzing formation of 3-hydroxykynurenine (3-HK) from kynurenine (Kyn), a tryptophan (Trp) metabolite, might contribute to development of MetS as suggested by non-expression of KMO genes in human fat tissue and elevated serum concentrations of Kyn and its metabolites, kynurenic (KYNA) and anthranilic (ANA) acids, in diabetic patients and Zucker fatty rats (ZFR). Markers of KMO deficiency: decreased 3-HK and elevated Kyn, KYNA and ANA, were observed in brains and spinal fluids of SP, and in brains and serum of experimental animals with genetically- or pharmacologically-induced KMO deficiency. However, elevated concentrations of ANA and decreased 3-HK were reported in serum of SP without concurrent increase of Kyn and KYNA. Present study aimed to re-assess serum Kyn metabolites (HPLC-MS) in a sub-group of SP with elevated KYNA. We found increased Kyn concentrations (by 30%) and Kyn:Trp ratio (by 20%) in serum of SP with elevated KYNA concentrations (by 40%). Obtained results and our previous data suggest that peripheral KMO deficiency might be manifested by, at least, two different patterns: elevated ANA with decreased 3-HK; and elevated KYNA and KYN. The latter pattern was previously described in type 2 diabetes patients and might underline increased predisposition of SP to development of MetS. Assessment of peripheral KMO deficiency might identify SP predisposed to MetS. Attenuation of the consequences of peripheral KMO deficiency might be a new target for prevention/treatment of obesity and diabetes in SP.

Introduction

Increased predisposition of Schizophrenia Patients (SP) and their first-degree relatives to development of obesity and insulin resistance suggests common signaling pathway between schizophrenia and metabolic syndrome (MetS) [1]. Dysregulation of kynurenine (Kyn) metabolism was proposed as one of the mechanisms of MetS [2-11]. Elevated serum concentrations of Kyn and its down-stream derivative, kynurenic acid (KYNA), were observed in type 2 diabetes [12] and in Zucker Fatty Rats (ZFR), an experimrntal model of MetS [13]suggesting deficiency of kynurenine-3-monooxygenase (KMO), a key enzyme of Kyn down-stream metabolism [14]. There are converging evidences of KMO deficiency in SP. Kyn is formed from Trp during the initial phase of KP [14]. Further metabolism of KYN is trifurcated into production of 3-hydroxyKyn (3-HK), catalyzed by vitamin B2-dependent Kyn-3-monooxygenase (KMO); kynurenic acid (KYNA) and anthranilic acid (ANA), catalyzed by vitamin B6-dependent Kyn-aminotransferase (KAT) and kynureninase (Kynase), resp (Figure 1A) [15]. “KYNA hypothesis of schizophrenia” [16] was initiated by a discovery of KMO deficiency in Broadmann area of brain of schizophrenia patients (SP) [17], and was supported by findings of elevated KYNA concentrations in brains [18] and CSF [19] of SP and by observations of KYNA-induced schizophrenia-like symptoms in experimental animals [20], including disruption of pre-pulse inhibition [21] and impairment of cognitive functions [22], and damage of spinal cord myelin [23] and impairment of oligodendrocyte viability [24]. KMO deficiency increased availability of Kyn as a substrate for unsaturated enzymes, KAT and Kynase, and, therefore, shifts downstream metabolism of Kyn from formation of 3-HK toward production of KYNA and ANA [15]. It was suggested that KYNA contributed to up-regulation of brain dopamine receptors, the hall mark of schizophrenia, via its antagonism to NMDA and a7-nicotinic acetylcholine receptors [18]. Besides the brain (e.g., glial cells), Kyn, KYNA, ANA, and 3-HK are formed by peripheral tissues (e.g., macrophages, pancreatic cells, adipocytes) [5,25,26]. All four markers of KMO deficiency, i.e., elevated Kyn, KYNA and ANA and decreased 3-HK, were observed not only in brain but in serum of experimental animals with KMO deficiency, induced by vitamin B2-deficient diet [27,28] or by knockout of gene, that encodes KMO [29,30]. However, in clinical studies, only elevated ANA and decreased 3-HK concentrations were observed in serum of SP without concurrent increase of Kyn and KYNA [15,31]. Therefore, we were interested to expand our previous study [9] by assessing serum KP metabolites in a subgroup of SP with elevated KYNA.

Figure 1

Different patterns of peripheral KMO deficiency in schizophrenia patients.

Materials and methods

Patients

Overnight fasting blood samples from SP (diagnosed according to DSM-V) with serum concentrations of KYNA higher than in controls (three men and four women, age range from 38 to 56 years) were selected for analysis of Kyn and its metabolites. All patients were taking anti-psychotic medication: Abilify (three patients), Haloperidol (two patients) and Haloperidol decanoate injections (two patients).

Healthy Subjects (Controls)

There were 12 subjects (6 females and 6 males, age range from 32 to 64 years). Study was approved by Tufts Medical Center IRB.

Assessment of kynurenine metabolites

Serum samples were stored at −50°C until analysis. ANA, Trp, Kyn, KYNA and 3-HK concentrations were analyzed by modified HPLC–mass spectrometry method as described elsewhere [15].

Statistical analysis

Results are presented as mean ± standard error (Trp and Kyn in µM and AA, KYNA and 3-HK in nM). Statistical significance was assessed by unpaired t test with Welch correction.

Results

KYNA concentrations in studied SP were higher (approximately by 40%) in comparison with controls. Kyn concentrations were elevated by 30%. Kyn:Trp ratio, an indicator of activity of tryptophan-2,3-dioxygenase (TDO), the first and rate-limiting enzyme of Trp – Kyn pathway, TDO activity, was increased by 20%. There was no statistically significant difference between concentrations of Trp, 3-HK and ANA in SP and controls (Table 1).

Table 1

Serum concentrations of Kyn metabolites in schizophrenia patients.

	Controls #(n=12)	Schizophrenia P *(n=7)
Tryptophan (µM)	68.90 ± 2.49	74.22 ± 5.28	ns
Kynurenine (µM)	1.76 ± 0.09	2.32 ± 0.12	0.02
Kyn × 100: Trp	2.56 ± 0.35	3.47 ± 0.20	0.03
3-HK (nM)	19.55 ± 3.14	11.85 ± 4.09	ns
KYNA (nM)	35.78 ± 3.59	49.23 ± 4.02	0.02
ANA (nM)	21.65 ± 5.99	23.92 ± 5.86	ns

mean + standard error;

unpaired t test with Welch correction

Abbreviations: KYNA: kynurenic acid; ANA : anthranilic acid; 3-HK : 3-HydroxyKynurenine.

Discussion

Present results (together with our previously published data) suggest that peripheral KMO deficiency is a common feature of MetS and schizophrenia. Experimental data suggested, at least, four potential clinical markers of KMO deficiency: elevation of KYN, ANA, KYNA and decrease of 3-HK serum concentrations. However, only two markers, elevated ANA and decreased 3-HK serum concentrations, were reported in SP without concurrent elevation of Kyn and KYNA concentrations [15,31]. In the present study of a sub-group of SP with higher than controls KYNA concentration, we observed elevation of serum concentrations of Kyn without concurrent elevation of ANA and decrease of 3HK concentrations. Notably, we observed a significant increase of Kyn:Trp ratio, suggesting activation of Trp conversion into Kyn catalyzed either by inflammation-induced indoleamine-2,3-dioxygenase (IDO) or by stress-induced TDO [14], while successful metformin treatment of insulin resistance was reported recently to be associated with down-regulation of the Trp - Kyn pathway [32]. TDO activation was previously described in prefrontal cortex of SP [33]. Therefore, elevated serum concentration of Kyn (and Kyn:Trp ratio) might be a result of KMO deficiency and/or IDO/TDO activation. Present data and our previous report suggested the existence of, at least, two patterns of peripheral KMO deficiency in SP: elevated ANA with decreased 3-HK (without changes of Kyn and KYNA) (Figure 1B); and elevated Kyn and KYNA (without changes of ANA and 3-HK) (Figure 1C). The latter pattern of peripheral KMO deficiency, i.e., elevation of both KYN and KYNA without elevation of ANA, was described in type 2 diabetes [34] and might underline increased predisposition of SP to MetS. Notably, both astrocytes and fat tissue do not express KMO genes [35,36]. Peripherally produced Kyn, ANA and 3-HK (but not KYNA) might contribute to central pathology by crossing blood brain barrier (BBB) [37] and entering a pool of centrally formed Kyn metabolites [38]. Dysregulation of Trp – Kyn pathway was suggested as a common signaling pathway for schizophrenia and Metabolic Syndrome in schizophrenia [9,13,15]. Elevated serum concentrations of KYNA, indicative of KMO deficiency, were observed in ZFR [13], and associated with weight gain in humans [39]. KYNA and KYN are endogenous ligands to aryl hydrocarbon receptor (AHR) that regulates xenobiotic-metabolizing enzymes such as aryl hydrocarbon hydroxylase (cytochrome P450) in humans and rodents [40]. AHR over-activation promoted while AHR deficiency protected mice from diet-induced obesity [41,42]. Therefore, peripheral KMO deficiency might contribute to metabolic abnormalities in SP via activation of AHR by increased formation of down-stream Kyn metabolites. Further studies might explore the use of evaluation of serum concentrations of Kyn and its down-stream metabolites in identification of SP at risk for development of MetS. Modulation of down-stream Kyn metabolism (by, e.g., inhibitors of KYNA and ANA formation) might be a new target for prevention/treatment of obesity in SP.